middl
east
respiratori
syndrom
coronaviru
merscov
becam
global
human
health
threat
sinc
first
document
human
effici
vaccin
prophylaxi
human
hotspot
infect
eg
saudi
arabia
necessari
commerci
vaccin
yet
approv
studi
chimer
dna
construct
design
encod
influenza
na
protein
flank
immunogen
amino
acid
aa
merscov
spike
protein
use
gener
chimer
construct
novel
recombin
vaccin
strain
pandem
influenza
viru
merscov
gener
chimer
bival
chimer
bival
vaccin
strain
compris
recombin
vaccin
express
ha
chimer
na
pandem
interestingli
increas
replic
effici
gener
vaccin
strain
observ
compar
vaccin
strain
lack
merscov
spike
peptid
insert
balbc
mice
inactiv
chimer
bival
vaccin
induc
potent
specif
neutral
antibodi
merscov
novel
approach
succeed
develop
recombin
influenza
viru
potenti
use
bival
vaccin
merscov
approach
provid
basi
futur
develop
chimer
influenzabas
vaccin
merscov
virus
softwar
mm
formal
analysi
investig
mm
ak
re
gk
maa
writingorigin
draft
prepar
msupervis
gk
maa
fund
acquisit
rw
gk
maa
author
revis
approv
final
manuscript
novel
human
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
first
detect
septemb
saudi
arabia
patient
show
fever
short
breath
cough
expector
sinc
first
case
merscov
spread
rapidli
around
world
human
infect
merscov
includ
death
report
four
contin
asia
europ
africa
north
america
juli
accord
case
report
countri
arabian
peninsula
especi
saudi
arabia
use
selflimit
virus
vector
immunogen
protein
merscov
appli
mani
studi
instanc
one
studi
engin
recombin
human
adenovir
vector
encod
full
protein
domain
protein
isol
adenobas
vaccin
evalu
balbc
mice
found
induc
tcell
respons
neutral
antibodi
nab
merscov
similarli
recombin
modifi
vaccinia
viru
express
full
protein
develop
vacciniabas
vaccin
evalu
merscov
balbc
mice
show
signific
induct
humor
cellmedi
immun
nab
addit
use
balbc
mice
immun
venezuelan
equin
enceph
viru
replicon
particl
contain
protein
result
reduct
viral
titer
nearli
undetect
level
day
post
infect
pi
increas
nab
vesicular
stomat
viru
vsv
express
spike
gene
merscov
induc
immunolog
tcell
respons
viru
neutral
rhesu
monkey
vsv
merscov
singl
immun
influenza
respiratori
communic
diseas
caus
influenza
virus
iv
classifi
antigen
base
distinct
nucleoprotein
np
four
genera
influenzaa
virus
iav
influenzab
virus
ibv
influenzac
virus
icv
influenzad
virus
idv
iv
singlestrand
segment
viral
rna
genom
vrna
iav
ibv
contain
eight
segment
icv
idv
contain
seven
segment
genom
eight
segment
iav
translat
viral
protein
due
wellstudi
safeti
profil
iav
easi
propag
product
use
either
embryon
chicken
egg
cell
cultur
system
sever
studi
use
recombin
iav
either
express
certain
immun
modul
anticanc
protein
combat
cancer
cell
oncolyt
viru
yang
et
al
synthes
short
peptid
amino
acid
aa
residu
spike
protein
merscov
posit
calpdtpstltprsvrsvpgemrla
elicit
nab
mice
rabbit
merscov
herein
use
recombin
influenza
vector
express
immunogen
short
peptid
residu
spike
protein
merscov
elicit
immun
merscov
short
peptid
insert
neuraminidas
gene
product
bival
vaccin
influenza
merscov
short
immunogen
peptid
calpdtpstltprsvrsvpgemrla
merscov
spike
glycoprotein
insert
stalk
region
na
gene
influenza
viru
use
design
primer
new
recombin
na
carri
short
peptid
merscov
chimer
bival
success
construct
recombin
ligat
clone
vector
figur
use
eightplasmid
revers
genet
system
recombin
control
viru
chimer
bival
candid
bival
viru
gener
revers
genet
system
gener
chimer
bival
viru
illustr
figur
rescu
bival
control
virus
propag
spf
embryon
chicken
egg
three
passag
safe
embryo
mortal
h
post
infect
pi
insert
sequenc
immunogen
peptid
merscov
spike
glycoprotein
stabl
without
associ
adapt
mutationsdelet
na
gene
three
success
passag
egg
replic
effici
chimer
viru
chimer
bival
versu
parent
counterpart
without
insert
merscov
peptid
wt
compar
mdckii
cell
chimer
viru
higher
replic
effici
measur
tcid
differ
time
point
compar
parent
wt
viru
p
figur
four
group
mice
intramuscularli
inject
inactiv
chimer
bival
wt
merscov
vaccin
phosphat
buffer
salin
pb
collect
sera
vaccin
group
inactiv
chimer
bival
wt
reveal
increas
antibodi
titer
two
week
post
vaccin
wpv
week
hemagglutin
inhibit
hai
titer
wane
booster
vaccin
week
chimer
bival
vaccin
show
signific
increas
mean
hai
titer
reach
log
week
respect
comparison
controlpb
group
inactiv
wt
control
group
show
statist
signific
increas
hai
titer
week
comparison
controlpb
merscov
inactiv
group
result
reveal
vaccin
mice
potent
immunogen
respons
viru
shown
figur
plaqu
reduct
neutral
test
prnt
show
high
signific
neutral
titer
inactiv
merscov
vaccin
mice
titer
log
wpv
chimer
bival
vaccin
mice
show
signific
increas
p
valu
nab
merscov
reach
log
week
compar
control
group
demonstr
figur
controlpb
inactiv
wt
group
show
nab
sera
merscov
throughout
durat
experi
examin
protect
effici
vaccin
mice
viral
infect
wild
type
inocul
balbc
mice
pb
control
chimer
bival
vaccin
group
studi
recombin
chimer
bival
viru
posit
control
inactiv
wt
show
bodi
weight
loss
till
day
pi
compar
control
group
mice
infect
wild
type
control
group
decreas
weight
day
day
pi
lead
euthanasia
figur
mortal
rate
control
mice
start
day
pi
increas
gradual
day
pi
day
pi
figur
result
point
vaccin
either
virus
protect
mice
influenzainduc
mortal
merscov
pandem
influenza
virus
among
import
emerg
infecti
diseas
repres
seriou
public
health
challeng
develop
effect
bival
vaccin
influenza
merscov
infect
urgent
requir
especi
area
virus
cocircul
thu
design
novel
strategi
prevent
merscov
influenza
infect
demand
previou
studi
show
aa
merscov
spike
epitop
elicit
robust
neutral
activ
block
viral
infect
herein
develop
novel
recombin
bival
vaccin
merscov
use
rescu
influenza
viru
carri
short
immunogen
peptid
protein
na
gene
short
peptid
merscov
insert
posit
aa
nastalk
domain
influenza
uniqu
site
select
base
distinct
natur
delet
correspond
neuraminidas
subtyp
isol
egypt
sinc
safeti
reason
prefer
test
na
instead
shuttl
merscov
spike
immunogen
epitop
revers
genet
use
gener
recombin
influenza
viru
sinc
allow
manipul
influenza
viru
genom
addit
chang
remov
genet
determin
respons
viru
virul
short
immunogen
peptid
insert
stalk
region
na
use
recombin
ligat
influenza
viral
vector
system
merscov
potenti
advantag
includ
abil
largescal
product
engin
viru
embryon
chicken
egg
stimul
mucos
system
immun
respons
studi
use
inactiv
influenza
vaccin
due
safeti
measur
comparison
influenza
live
attenu
vaccin
ilav
caus
influenza
likeil
headach
runni
nose
sore
throat
cough
ilav
limit
pregnant
immunecompromis
patient
vaccin
viru
grew
poorli
embryon
chicken
egg
compar
growth
previou
season
isol
result
manufactur
struggl
meet
demand
overcom
limit
replic
rescu
viru
addit
ha
modifi
na
segment
strain
use
gener
chimer
bival
candid
vaccin
strain
develop
vaccin
seed
viru
replic
well
without
associ
adapt
mutat
previou
studi
indic
insert
report
gene
influenza
viral
ns
naencod
segment
success
insert
report
gene
influenza
viral
genom
associ
inconst
express
level
genom
instabl
dispos
foreign
insert
strategi
insert
short
immunogen
peptid
aa
nacod
region
improv
viru
replic
novel
chimer
bival
vaccin
mice
show
signific
increas
nab
merscov
occur
week
mice
vaccin
chimer
bival
viru
protect
mortal
bodi
weight
loss
week
challeng
wild
type
viru
week
appar
declin
antibodi
level
specif
immun
respons
observ
like
relat
tradit
phenomenon
name
selflimit
resolut
neutral
antibodi
titer
decreas
follow
booster
immun
respons
administr
antigen
sever
studi
show
protect
efficaci
merscov
vaccin
posit
correl
evok
neutral
antibodi
titer
serum
vaccin
anim
result
accord
result
viral
platform
chimer
virus
carri
spike
protein
provid
nab
merscov
summari
demonstr
new
platform
gener
replicationcompet
recombin
influenza
chimer
bival
viru
contain
immunogen
short
peptid
merscov
na
gene
use
revers
genet
technolog
rescu
chimer
bival
influenza
viru
could
replic
well
propag
multipl
passag
embryon
egg
novel
recombin
bival
iav
provid
nab
merscov
hai
antibodi
influenza
virus
vaccin
mice
futur
studi
evalu
candid
vaccin
protect
capac
murinechalleng
model
nonhuman
primat
first
step
human
trail
gener
safe
well
replic
candid
strain
human
vaccin
recommend
insert
short
immunogen
aa
peptid
calpdtpstltprsvrsvpgemrla
spike
glycoprotein
merscov
na
gene
viru
illustr
figur
construct
chimer
plasmid
two
pcr
fragment
amplifi
use
tattggtctcagggagcaaaagcaggagt
atatggtctcactgcgaggtgtgagagtactaggtgtgtcagg
aagagcacatgtttcaatctgattttgatt
fragment
attggtctcagcagtgtgcgctctgttccaggtgaaatgcgcttggcatgcaatcaaagcgtc
attacttatg
atatggtctcgtattagtagaaacaaggagtttttt
fragment
use
phusion
master
mix
thermo
waltham
usa
total
reaction
master
mix
forward
revers
primer
fragment
templat
dna
mix
cycler
condit
c
min
follow
three
step
c
c
c
min
cycl
final
extens
c
min
two
fragment
load
agaros
electrophoresi
band
purifi
use
qiaquick
gel
purif
kit
qiagen
hilden
germani
purif
two
fragment
digest
bsa
neb
ipswich
usa
ligat
two
fragment
bsmbi
linear
done
use
dna
ligas
promega
madison
wi
usa
overnight
c
transform
use
top
compet
cell
perform
accord
instruct
coloni
select
miniprep
purifi
construct
prepar
sequenc
macrogen
facil
macrogen
seoul
south
korea
ha
segment
amplifi
digest
use
bsmbi
neb
ipswich
usa
ligat
linear
previous
describ
gener
plasmid
carri
eight
gene
segment
highyield
viru
suppli
st
jude
children
research
hospit
usa
use
eightplasmid
revers
genet
system
recombin
wt
chimer
bival
virus
gener
use
respect
describ
previous
briefli
day
transfect
cell
cocultur
ratio
incub
c
co
day
transfect
eight
desir
dna
plasmid
per
plasmid
mix
miru
madison
wi
usa
per
plasmid
optimem
reduc
serum
medium
invitrogen
carlsbad
ca
usa
incub
min
room
temperatur
afterward
volum
optimem
medium
ad
mixtur
mixtur
ad
drop
wise
cell
incub
c
co
h
transfect
mixtur
replac
ml
optimem
contain
antibioticantimycot
mixtur
bovin
serum
albumin
cell
incub
overnight
co
subsequ
addit
ml
optimem
contain
penstrep
bovin
serum
albumin
bsa
chloromethyl
keton
tpck
treat
trypsin
sigmaaldrich
st
loui
mi
usa
ad
cell
incub
h
cultur
supernat
harvest
clarifi
lowspe
centrifug
inject
supernat
specificpathogenfre
spf
embryon
chicken
egg
mdckii
cell
standard
hemagglutin
test
ha
use
detect
recombin
virus
allanto
fluid
embryon
chicken
egg
mdckii
cell
harvest
recombin
virus
harvest
propag
spf
embryon
chicken
egg
three
passag
na
gene
gener
rescu
virus
amplifi
sequenc
test
stabil
insert
short
peptid
mdckii
cell
cultur
plate
overnight
confluent
monolay
chimer
bival
wt
virus
infect
multipl
infect
moi
h
c
co
incub
inoculum
remov
wash
pb
total
amount
ml
dmem
infect
media
tpck
treat
trypsin
ad
cell
supernat
infect
cell
harvest
specif
time
point
titrat
mdckii
cell
use
tissu
cultur
infecti
dose
tcid
accord
reed
muench
protocol
novel
rescu
viru
chimer
bival
wt
propag
spf
embryon
chicken
egg
merscov
grown
cell
collect
harvest
viru
clear
cell
debri
centrifug
g
min
harvest
virus
inactiv
use
formaldehyd
mix
well
h
c
inactiv
viral
particl
pellet
care
layer
ml
inactiv
viru
onto
ml
sucros
centrifug
tube
centrifug
ultracentrifug
sorval
mtx
thermo
waltham
usa
rpm
c
h
pellet
suspend
pb
viru
titer
measur
ha
assay
total
protein
measur
use
nanodrop
thermo
fisher
scientif
waltham
usa
equal
protein
content
inactiv
viru
mix
alum
adjuv
vv
min
suspens
use
immun
femal
weeksold
balbc
mice
obtain
anim
hous
nrc
egypt
mice
divid
four
group
seven
micegroup
three
group
mice
intramuscularli
immun
three
form
inactiv
chimer
bival
wt
merscov
vaccin
remain
group
serv
neg
control
inject
steril
pb
anim
receiv
booster
dose
wpv
sera
collect
wpv
collect
sera
test
antibodi
merscov
virus
use
hai
prnt
cell
prnt
assay
perform
previous
describ
determin
neutral
capac
elicit
antibodi
sera
immun
balbc
mice
merscov
briefli
collect
sera
firstli
heat
min
water
bath
inactiv
sera
twofold
serial
dilut
fb
dilut
sera
dilut
equal
volumeamount
plaqu
form
unit
fb
suppli
h
coincub
serumviru
mixtur
mixtur
dispens
individu
tissu
cultur
plate
contain
confluent
monolay
cell
cell
monolay
incub
togeth
serumviru
mixtur
c
h
allow
viru
adsorpt
infect
vero
monolay
wash
pb
suppli
agaros
overlay
contain
mem
media
agaros
penicillinstreptomycin
penstrep
left
solidifi
plate
incub
format
visibl
viral
plaqu
h
cell
monolay
fix
formaldehyd
solut
h
stain
crystal
violet
solut
min
rt
eventu
plate
wash
water
visual
plaqu
percent
inhibit
calcul
follow
plaqu
reduct
viru
control
plaqu
count
sampl
plaqu
count
viru
control
plaqu
count
prnt
defin
reciproc
antibodi
dilut
requir
reduc
number
merscov
plaqu
cell
rel
control
well
eight
week
post
vaccin
immun
mice
chimer
bival
wt
inactiv
vaccin
anesthet
inject
intraperiton
ketamin
dose
adjust
bodi
weight
bwt
influenza
viru
wild
type
administ
intranas
infecti
dose
tcid
immun
control
pb
group
mice
show
weight
loss
initi
bodi
weight
euthan
document
dead
bodi
weight
monitor
daili
wpi
anim
trial
studi
conduct
accord
guidelin
egyptian
anim
welfar
regul
legisl
ethic
committe
nrc
egypt
approv
anim
trial
number
regul
anim
welfar
assur
identif
number
experi
perform
biosafeti
level
contain
laboratori
approv
use
local
author
nrc
egypt
merscov
neutral
assay
class
iii
biolog
safeti
cabinet
seaiii
bsc
germfre
ormond
beach
fl
usa
use
